Motus GI is assessing potential strategic partnership opportunities for the Pure-Vu System with established medical device companies and distributors with commercial operations across the EU.
EXPEDITE Study Initiated by Boston Medical Center to Evaluate Clinical Effectiveness of Pure-Vu® System for Improving Bowel Preparation Rates
The investigator-initiated study will assess the ability of the Pure-Vu System to accelerate time to a successful colonoscopy in a real-world setting. Study to enroll up to 100 hospital inpatient and outpatient participants in need of a diagnostic colonoscopy.
The company reived 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the second-generation Pure-Vu® System (“Pure-Vu® GEN2”) to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.
4/29/19: Full Clinical Results from the REDUCE Study of the Pure-Vu System to be Presented at Digestive Disease Week 2019
The company reports that the full clinical results from the Company’s REDUCE Study (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) evaluating the Pure-Vu System will be presented at Digestive Disease Week® 2019 - May 18 - 21, 2019 in San Diego, CA.
Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System
3/19/19: The Pure-Vu® System is a U.S. Food and Drug Administration (“FDA”) cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.
Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology
2/19/19: Pure-Vu® System is a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques.
5/21/18: “With colorectal cancer being one of the top three most commonly diagnosed cancers in the world, accounting for over 1.4 million new cases and 700,000 deaths, it is important that we bring the Pure-Vu® System to patients across the globe over the next several years,” said Mark Pomeranz, CEO of Motus GI.